Daniel Hochhauser

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.

Journal: The New England journal of medicine
Published: June 02, 2025

Impact of Long-Term Chemotherapy on Outcomes in Pancreatic Ductal Adenocarcinoma: A Real-World UK Multi-Centre Study.

Impact of Long-Term Chemotherapy on Outcomes in Pancreatic Ductal Adenocarcinoma: A Real-World UK Multi-Centre Study.

Journal: Cancers
Published: April 25, 2025

Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responses.

Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responses.

Journal: Cell
Published: November 27, 2024

Comprehensive Examination of Cholangiocarcinoma Patients Treated with Novel Targeted Therapies after Extended Molecular Profiling on Liquid Biopsies.

Comprehensive Examination of Cholangiocarcinoma Patients Treated with Novel Targeted Therapies after Extended Molecular Profiling on Liquid Biopsies.

Journal: Cancers
Published: December 23, 2023

Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responses.

Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responses.

Journal: Cell
Published: January 07, 2023

T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer.

T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer.

Journal: Future oncology (London, England)
Published: July 19, 2022

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 14, 2022

PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.

PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.

Journal: British journal of cancer
Published: May 19, 2022

Homopolymer switches mediate adaptive mutability in mismatch repair-deficient colorectal cancer.

Homopolymer switches mediate adaptive mutability in mismatch repair-deficient colorectal cancer.

Journal: Nature genetics
Published: March 04, 2022

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.

Journal: Cell death & disease
Published: November 11, 2021

Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous in vivo delivery of tyrosine kinase inhibitors and kinase activity biosensors.

Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous in vivo delivery of tyrosine kinase inhibitors and kinase activity biosensors.

Journal: Nanoscale
Published: November 03, 2021

The role of PARP inhibitors in gastrointestinal cancers.

The role of PARP inhibitors in gastrointestinal cancers.

Journal: Critical reviews in oncology/hematology
Published: June 13, 2021
Showing 1-12 of 60

Last Updated: 09/26/2026